SciSparc (SPRC) Adds AI Expert as It Evaluates Agentic AI Entry

SciSparc (SPRC) appointed Prof. Jacob Nagel to its Scientific Advisory Board for AI and Cybersecurity. The company is evaluating potential technologies, partnerships, and opportunities as it considers entry into Agentic AI.

Original reporting
Published Nov 16, 2026, 12:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 12:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
SciSparc (SPRC) Adds AI Expert as It Evaluates Agentic AI Entry — source image
Decision brief

The 30-second read

$SPRCNeutralLow
01

Why it matters

The advisory board addition is a strategic signal but lacks immediate material effect.

02

Market read

Minor news for a microcap; limited trading relevance.

03

What to watch

Potential future partnerships or technology licensing stemming from the advisory role.

Relevance 4/10Novelty 3/10Timing: immediate

Background

SciSparc is a small AI-focused company exploring entry into Agentic AI.

Company-level read

Ticker impact

$SPRCNeutralLow confidence
Context

SciSparc appointed Prof. Jacob Nagel to its Scientific Advisory Board for AI and Cybersecurity.

Expected impact

modest upward pressure as investors view AI focus positively

Evidence & confidence

No concrete deal, funding, or revenue impact disclosed; only a personnel change.

Market effects

Highlights growing interest in Agentic AI within the AI/tech sector.

Limited to US microcap investors.

Low; no broader market impact.

Counterpoint

The appointment may be symbolic with no real operational impact, limiting any price move.

Key entities

  • SciSparc Ltd.

    AI company evaluating Agentic AI entry.

  • Prof. Jacob Nagel

    AI and cybersecurity expert joining advisory board.

Related articles

$SPRCMedAI 8/10

SPRC Stock Jumps As SciSparc Advances Tourette Trial And AI Pivot

SciSparc Ltd. (SPRC) stock surged 39.44% on October 26, 2026, driven by positive sentiment around its Tourette syndrome drug trial and AI initiatives. The company's subsidiary, NeuroThera Labs, advanced its drug candidate SCI-110 into a Phase IIb trial, while its AI division, CliniQuantum, demonstrated significant performance improvements. SPRC trades at a fraction of its book value, reflecting both skepticism and potential value if its pipeline or AI initiatives gain traction.

$SPRCMedAI 8/10

Yale is one of three centers ready to receive a Tourette’s trial drug

SciSparc (Nasdaq: SPRC) announced that its subsidiary, NeuroThera Labs (TSXV: NTLX), has completed manufacturing and obtained regulatory approval for its Phase IIb clinical trial of SCI-110, a drug for Tourette Syndrome. The trial will be conducted at three sites, including Yale and Tel Aviv Sourasky Medical Center. SCI-110 combines dronabinol and PEA, aiming to address unmet treatment needs for TS. Patient enrollment is expected to begin soon, marking a significant milestone for NeuroThera.

$SPRCMed

Why is Scisparc stock surging today?

Scisparc (SPRC) stock rose 37% in pre-market trading after announcing a strategic shift to AI-powered technologies, focusing on cybersecurity and fintech. The Tel Aviv-based firm, previously a clinical-stage pharmaceutical developer, plans to explore agentic AI opportunities but cautioned no guarantees. The surge contrasts with broader tech selloffs due to inflation fears. No analyst upgrades accompanied the news, with recent ratings being 'hold' and 'sell'.

$SPRCHighAI 8/10

Top Biotech Gainers: SPRC On Watch, AVTR, NEO Boost Full-Year Outlook, SMTI Scooped Up

Biotech gainers included SciSparc (SPRC) after its subsidiary NeuroThera Labs completed internal validation of a quantum sampling platform. Avantor (AVTR) rose after Q2 results and raised 2026 adjusted EPS to $0.80-$0.83. NeoGenomics (NEO) lifted 2026 revenue guidance to $802-$806M. Other movers: Alvotech (ALVO) on FDA facility inspection, Sanara MedTech (SMTI) to be acquired by MiMedx (MDXG), and LB Pharmaceuticals (LBRX) after a ~$150M private placement.